Kimberly Umans

777 total citations · 1 hit paper
12 papers, 582 citations indexed

About

Kimberly Umans is a scholar working on Pathology and Forensic Medicine, Immunology and Molecular Biology. According to data from OpenAlex, Kimberly Umans has authored 12 papers receiving a total of 582 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 4 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Kimberly Umans's work include Multiple Sclerosis Research Studies (5 papers), Immunotherapy and Immune Responses (4 papers) and Alzheimer's disease research and treatments (3 papers). Kimberly Umans is often cited by papers focused on Multiple Sclerosis Research Studies (5 papers), Immunotherapy and Immune Responses (4 papers) and Alzheimer's disease research and treatments (3 papers). Kimberly Umans collaborates with scholars based in United States, United Kingdom and Czechia. Kimberly Umans's co-authors include Samantha Budd Haeberlein, Stephen Salloway, Frederik Barkhof, Patrick Burkett, Fiona Forrestal, Karen Smirnakis, Jerome Barakos, Derk D. Purcell, Priya Singhal and Spyros Chalkias and has published in prestigious journals such as Neurology, Journal of Thrombosis and Haemostasis and JAMA Neurology.

In The Last Decade

Kimberly Umans

11 papers receiving 573 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

2021 411 citations Stephen Salloway, Spyros Chalkias et al. JAMA Neurology profile →

Peers

Countries citing papers authored by Kimberly Umans

Since Specialization

Citations

This map shows the geographic impact of Kimberly Umans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly Umans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly Umans more than expected).

Fields of papers citing papers by Kimberly Umans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly Umans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly Umans. The network helps show where Kimberly Umans may publish in the future.

Co-authorship network of co-authors of Kimberly Umans

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly Umans. A scholar is included among the top collaborators of Kimberly Umans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly Umans. Kimberly Umans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies 2023 ·Neurology ·Stephanie Loomis, (unknown), Carmen Castrillo‐Viguera, Kimberly Umans, Wenting Cheng, John O’Gorman, Richard A. Hughes, Samantha Budd Haeberlein, Christopher D. Whelan	25
2	Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease breakdown → 2021 ·JAMA Neurology ·Stephen Salloway, Spyros Chalkias, Frederik Barkhof, Patrick Burkett, Jerome Barakos, Derk D. Purcell, Joyce Suhy, Fiona Forrestal, Ying Tian, Kimberly Umans, Guanfang Wang, Priya Singhal, Samantha Budd Haeberlein, Karen Smirnakis	411
3	Considerations for the real‐world management of ARIA from the aducanumab phase 3 studies EMERGE and ENGAGE 2021 ·Alzheimer s & Dementia ·Patrick Burkett, Spyros Chalkias, Kimberly Umans, Carmen Castrillo‐Viguera, Derk D. Purcell, Jerome Barakos, (unknown), Karen Smirnakis, Samantha Budd Haeberlein	0
4	Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta 2017 ·Multiple Sclerosis Journal ·Gavin Giovannoni, Heinz Wiendl, Benjamin Turner, Kimberly Umans, (unknown), Wanda Castro-Borrero, Steven J. Greenberg, Peter McCroskery, Giorgio Giannattasio	3
5	Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies 2016 ·Multiple Sclerosis and Related Disorders ·Gavin Giovannoni, Ludwig Kappos, Ralf Gold, Bhupendra Khatri, Krzysztof Selmaj, Kimberly Umans, Steven J. Greenberg, Marianne T. Sweetser, Jacob Elkins, Peter McCroskery	44
6	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study 2016 ·BMC Neurology ·Ralf Gold, Ernst‐Wilhelm Radue, Gavin Giovannoni, Krzysztof Selmaj, Eva Havrdová, Dusan Stefoski, Till Sprenger, Xavier Montalbán, Stanley Cohan, Kimberly Umans, Steven J. Greenberg, (unknown), Jacob Elkins	39
7	Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta 2016 ·International Journal of MS Care ·Lahar Mehta, Kimberly Umans, (unknown), Randy Robinson, Jacob Elkins	9
8	Long-Term Safety of Daclizumab HYP in Patients with Relapsing-Remitting Multiple Sclerosis: 3-4 Year Results from the SELECTED Extension Study (P7.225) 2015 ·Neurology ·Ralf Gold, Gavin Giovannoni, Krzysztof Selmaj, Eva Havrdová, Dusan Stefoski, Ernst‐Wilhelm Radue, Till Sprenger, Xavier Montalbán, Kimberly Umans, Steven Greenberg, Jacob Elkins, (unknown), Marianne T. Sweetser	2
9	Proportion of Disease-Activity Free Patients with Relapsing-Remitting Multiple Sclerosis Following 1 Year of Treatment with Daclizumab High-Yield Process in the SELECT Study (P07.105) 2013 ·Neurology ·Eva Havrdová, Gavin Giovannoni, Dusan Stefoski, Kimberly Umans, Steven J. Greenberg, Lahar Mehta, Jacob Elkins	2
10	Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study 2013 ·Multiple Sclerosis Journal ·Eva Havrdová, Gavin Giovannoni, Dusan Stefoski, (unknown), Kimberly Umans, Lahar Mehta, Steven J. Greenberg, Jacob Elkins	25
11	Daclizumab HYP Monotherapy Improved Health-Related Quality of Life Parameters in Relapsing-Remitting Multiple Sclerosis: Findings of the SELECT Trial (P07.098) 2012 ·Neurology ·Krzysztof Selmaj, Eva Havrdová, Ralf Gold, SJ Greenberg, Kimberly Umans, Jacob Elkins	2
12	Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor‐1 (PAI‐1) 2004 ·Journal of Thrombosis and Haemostasis ·H.R. Lijnen, B. Van Hoef, Kimberly Umans, D Collen	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact